ĀÜĄņĀŅĀ×

Eva Chin, PhD, has a career that has spanned the academic and pharmaceutical industries, with previous positions at Pfizer, the University of Maryland, MyoTherapeutics, Cytokinetics and NMD Pharma. Her work has increasingly focused on targeting the underlying skeletal muscle pathologies in rare neuromuscular diseases, including DMD, ALS, SMA and myasthenia gravis. Dr. Chin has led or contributed to 10 programs moving from novel research idea to candidate nomination and into Phase 2/3 clinical trials, focusing on translational pharmacology and safety to support IND/CTA filings and Orphan Drug designation.

ā€

She obtained her PhD in physiology from the University of Waterloo in Canada and completed post-doctoral training at the University of Sydney, Australia, and UT Southwestern Medical Center in Dallas, focusing on the role of intracellular calcium in skeletal muscle fatigue, transcriptional regulation of gene expression and muscle plasticity. Dr. Chin has published more than 50 peer-reviewed articles and more than 100 conference abstracts and presentations focusing on skeletal muscle fatigue and disease mechanisms for metabolic disease, aging and neuromuscular diseases.